Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.
Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.
Genprex, Inc. (NASDAQ: GNPX) announced that the FDA has conditionally accepted the proprietary name REQORSA™ for its lead drug candidate targeting non-small cell lung cancer, previously known as GPX-001. This name approval is a critical step towards marketing the therapy and enhances the brand identity of Genprex. The REQORSA drug utilizes the ONCOPREX® nanoparticle delivery system and previously received Fast Track Designation from the FDA. Final approval of the name is contingent upon successful clinical trials and FDA product candidate approval.
Genprex, Inc. (GNPX) has promoted Eric Chapdelaine to Vice President of Manufacturing, reflecting the company’s progress in scaling its manufacturing operations. This comes as Genprex prepares for upcoming Phase I/II clinical trials of its lead candidate, GPX-001, in combination with AstraZeneca’s Tagrisso for non-small cell lung cancer (NSCLC). The company received FDA Fast Track Designation for GPX-001 in January 2020, aimed at improving treatment options for patients who have progressed on prior therapies.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, will present virtually at the Zooming with LD Micro event on October 14 at 11 a.m. ET. CEO Rodney Varner will lead the presentation followed by a Q&A session. Genprex focuses on developing technologies for cancer and diabetes patients, with its lead product candidate, GPX-001, aimed at treating non-small cell lung cancer (NSCLC). The FDA has granted GPX-001 Fast Track Designation for combination therapy with osimertinib for patients with EGFR mutations.
Genprex, Inc. (NASDAQ: GNPX) announced its participation in the upcoming Cell and Gene Meeting on the Mesa from October 12-16, 2020. Michael Redman, Executive VP and COO, will present on the company's innovative gene therapies targeting cancer and diabetes. The virtual event aims to tackle commercialization challenges in the cell and gene therapy sector, featuring on-demand presentations and live panels. Genprex's lead candidate, GPX-001, is in development for non-small cell lung cancer and received FDA's Fast Track Designation.
Genprex (NASDAQ:GNPX) announced its upcoming presentation at the LD 500 Virtual Investor Conference on September 1, 2020, at 1:20 p.m. ET. CEO Rodney Varner will discuss the company's product pipeline, highlighting GPX-001, which has received Fast Track Designation from the FDA for late-stage lung cancer treatment. The presentation will be available via live webcast on the conference and company websites. Genprex focuses on gene therapy advancements for cancer and diabetes, aiming to provide new treatment options.